Clarity Pharmaceuticals (CU6) Investor presentation summary

Vision and strategy

• Aims to build a leading pharmaceutical biotech based on Australian intellectual property, targeting blockbuster markets with high unmet needs.

• Focuses on discovery, rigorous clinical development, and commercialisation of innovative radiopharmaceuticals.

Product innovation and differentiation

• SAR-bisPSMA leverages proprietary dual PSMA targeting and copper isotopes for improved imaging and therapy.

• Offers extended shelf-life, flexible imaging windows, and higher tumour uptake compared to current agents.

• Holds two proprietary positions: chelator composition and dual targeting agent.

Clinical development and evidence

• Over 750 patients and 1,500+ scans across six trials in Australia and the US.

• Multiple Phase I-III trials (PROPELLER, CLARIFY, COBRA, AMPLIFY, Co-PSMA) demonstrate higher lesion detection, uptake, and clinical impact versus standard-of-care (SOC) PSMA PET agents.

• Next-day imaging with 64Cu-SAR-bisPSMA increases lesion detection by 82% and enables detection of smaller lesions.